Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097425 | 0.85 | FAAH (0.47) | FAAHALDH1A1LMNAMGLLTPSAB1 | |
| SCHEMBL5645313 | 0.80 | FAAH (0.49) | FAAHALDH1A1LMNAMGLLFNTA | |
| SCHEMBL5650694 | 0.79 | FAAH (0.43) | FAAHALDH1A1LMNAMGLLTPSAB1 | |
| SCHEMBL5650379 | 0.79 | FAAH (0.50) | FAAHALDH1A1LMNAMGLLFNTA | |
| SCHEMBL17275230 | 0.77 | SMN1; SMN2 (0.47) | FAAHALDH1A1LMNAMGLL | |
| SCHEMBL1911804 | 0.77 | FAAH (0.55) | FAAHALDH1A1LMNAMGLLFNTA | |
| SCHEMBL12686822 | 0.76 | TBXAS1 (0.41) | FAAHALDH1A1LMNATPSAB1TPSD1 | |
| SCHEMBL13097423 | 0.76 | FAAH (0.43) | FAAHALDH1A1LMNAMGLLFNTA | |
| SCHEMBL8295271 | 0.75 | FAAH (0.42) | FAAHALDH1A1LMNAMGLLMMP1 | |
| SCHEMBL27885322 | 0.75 | FAAH (0.47) | FAAHALDH1A1LMNAMGLLFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | FAAH 890/4885ALDH1A1 524/4885LMNA 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.